Literature DB >> 22526015

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone.

Todd A Davies1, Robert K Flamm, A Simon Lynch.   

Abstract

Tracking Resistance in the US Today (TRUST) 2008 surveillance data showed that 6% of Streptococcus pneumoniae were non-susceptible to ceftriaxone [minimum inhibitory concentration (MIC) ≥ 2 μg/mL] and that 8% of the ceftriaxone-non-susceptible isolates exhibited high-level resistance (MIC ≥ 8 μg/mL). Here we describe the activity of ceftobiprole against ceftriaxone-resistant isolates and characterise the genotypic traits associated with resistance. Thirty isolates with ceftriaxone MICs ≥ 8 μg/mL were analysed by sequencing of penicillin-binding protein (PBP) and murM genes. Sequencing of pbp1a, pbp2b and pbp2x showed nine PBP patterns, with the most common (n=17) being: PBP1a T371S (STMK motif), P432T (SRNVP motif); PBP2b T446A (SSNT motif), A619G (KTGTA motif); and PBP2x T338A and M339F (STMK motif), L364F, I371T, R384G, M400T, L546V (LKSGT motif); six isolates had the same pattern without the PBP2b A619G change. For these 23 isolates, MICs were 8 μg/mL for ceftriaxone, 4-8 μg/mL for penicillin and 0.5-2 μg/mL for ceftobiprole. The remaining seven isolates with higher MICs (ceftriaxone 8-32 μg/mL, penicillin 4-32 μg/mL and ceftobiprole 2-4 μg/mL) had fewer PBP active-site motif substitutions. The majority of isolates (17/30) had murM alleles similar to the wild-type, whilst the rest had alleles reflecting a mosaic structure. No murM alleles were associated with higher MICs. Against these 30 isolates, ceftobiprole was 4-16-fold more active than ceftriaxone. Widely described PBP and MurM substitutions probably account for the high ceftriaxone MICs (8 μg/mL) in the majority of isolates. However, seven isolates with ceftriaxone MICs of 8-32 μg/mL had fewer PBP substitutions in active-site motifs, suggesting either that there is another resistance mechanism or that unique PBP mutations may contribute to high-level β-lactam resistance.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526015     DOI: 10.1016/j.ijantimicag.2012.02.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Molecular characteristics of penicillin-binding protein 2b, 2x and 1a sequences in Streptococcus pneumoniae isolates causing invasive diseases among children in Northeast China.

Authors:  X Zhou; J Liu; Z Zhang; Y Liu; Y Wang; Y Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-14       Impact factor: 3.267

2.  A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Authors:  Samir S Awad; Alejandro H Rodriguez; Yin-Ching Chuang; Zsuszanna Marjanek; Alex J Pareigis; Gilmar Reis; Thomas W L Scheeren; Alejandro S Sánchez; Xin Zhou; Mikaël Saulay; Marc Engelhardt
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

Review 3.  Ceftobiprole for the treatment of pneumonia: a European perspective.

Authors:  Adamantia Liapikou; Catia Cillóniz; Antonio Torres
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

4.  Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015.

Authors:  Anne Santerre Henriksen; Jennifer I Smart; Kamal Hamed
Journal:  Infect Drug Resist       Date:  2018-08-28       Impact factor: 4.003

5.  Molecular Characterization of Penicillin-Binding Protein2x, 2b and 1a of Streptococcus pneumoniae Causing Invasive Pneumococcal Diseases in China: A Multicenter Study.

Authors:  Menglan Zhou; Lulu Wang; Ziran Wang; Timothy Kudinha; Yao Wang; Yingchun Xu; Zhengyin Liu
Journal:  Front Microbiol       Date:  2022-03-01       Impact factor: 5.640

Review 6.  New antibiotics for bad bugs: where are we?

Authors:  Matteo Bassetti; Maria Merelli; Chiara Temperoni; Augusta Astilean
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-08-28       Impact factor: 3.944

Review 7.  Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New Antibacterials.

Authors:  Eric Sauvage; Mohammed Terrak
Journal:  Antibiotics (Basel)       Date:  2016-02-17

8.  Serotype Distribution, Antimicrobial Susceptibility, and Multilocus Sequencing Type (MLST) of Streptococcus pneumoniae From Adults of Three Hospitals in Shanghai, China.

Authors:  Xin-Xin Li; Shu-Zhen Xiao; Fei-Fei Gu; Sheng-Yuan Zhao; Qing Xie; Zi-Ke Sheng; Yu-Xing Ni; Jie-Ming Qu; Li-Zhong Han
Journal:  Front Cell Infect Microbiol       Date:  2019-11-27       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.